ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit – Allarity Therapeutics (NASDAQ:ALLR)

By: Alex Freidmen







Unveiling the Shadows: Allarity Therapeutics Faces Securities Fraud Allegations

Rising Allegations Cast Dark Cloud Over Allarity Therapeutics

BENSALEM, Pa., Oct. 10, 2024 /PRNewswire/ — Allegations of securities fraud loom large over Allarity Therapeutics, Inc. (“Allarity” or the “Company”) with a potential class action lawsuit pending (ALLR).

Class Period: May 17, 2022July 19, 2024

Lead Plaintiff Deadline: November 12, 2024

Investors facing losses in their Allarity investments are urged to contact legal counsel to explore their rights in this class action.

The complaint alleges that, during the Class Period, there was a failure to disclose key information that misled investors.

To join the class action, no immediate action is necessary; individuals can seek their counsel or remain an absent member of the case.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com


See also  Apple Embraces Direct App Downloads from Developer Sites in EU - Apple (NASDAQ:AAPL)Apple Embraces Direct App Downloads from Developer Sites in EU